Refine Your Results

Click below to filter your search results

"Medications or Drugs"Undo
"Neonatal or Infant"Undo

Search Results

Return to List
Results 1–5 of 5
Title Date
1.

Subclinical Hypothyroidism in Pregnancy

Number 381

(Reaffirmed 2012)

ABSTRACT: Subclinical hypothyroidism is diagnosed in asymptomatic women when the thyroid-stimulating hormone level is elevated and the free thyroxine level is within the reference range. Thyroid hormones, specifically thyroxine, are essential for normal fetal brain development. However, data indic...

October 2007

PDF Format
2.

Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection

Number 455

(Reaffirmed 2013)

ABSTRACT: Numerous large clinical studies have evaluated the evidence regarding magnesium sulfate, neuroprotection, and preterm births. The Committee on Obstetric Practice and the Society for Maternal-Fetal Medicine recognize that none of the individual studies found a benefit with regard to their...

March 2010

PDF Format
3.

Prevention of Early-Onset Group B Streptococcal Disease in Newborns

Number 485

(Reaffirmed 2013, Replaces No. 279, December 2002)

ABSTRACT: In 2010, the Centers for Disease Control and Prevention revised its guidelines for the prevention of perinatal group B streptococcal disease. Although universal screening at 35–37 weeks of gestation and intrapartum antibiotic prophylaxis continue to be the basis of the prevention strateg...

April 2011

PDF Format
4.

Emergent Therapy for Acute-Onset Severe Hypertension with Preeclampsia and Eclampsia

Number 514

ABSTRACT: Acute-onset, persistent (lasting 15 minutes or more), severe systolic (greater than or equal to 160 mm Hg) or severe diastolic hypertension (greater than or equal to 110 mm Hg) or both in pregnant or postpartum women with preeclampsia or eclampsia constitutes a hypertensive emergency. Se...

December 2011

PDF Format
5.

Magnesium Sulfate Use in Obstetrics

Number 573

ABSTRACT: The U.S. Food and Drug Administration advises against the use of magnesium sulfate injections for more than 5–7 days to stop preterm labor in pregnant women. Based on this, the drug classification was changed from Category A to Category D, and the labeling was changed to include this new...

September 2013

PDF Format